<DOC>
	<DOCNO>NCT01832727</DOCNO>
	<brief_summary>The primary objective follow : Phase 1b : - To determine maximum tolerate dose ( MTD ) oprozomib give orally , daily , 2 different schedule . - To evaluate safety tolerability Phase 2 : - To estimate overall response rate ( ORR ) . - To evaluate safety tolerability</brief_summary>
	<brief_title>Phase 1b/2 , Multicenter , Open-label Study Oprozomib Dexamethasone Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key Diagnosis multiple myeloma measureable disease Patients require therapy relapse and/or refractory last therapy treat least 1 , 5 line multiple myeloma therapy . Prior carfizolmib require allow patient least 2 cycle carfilzomib alone combination dose least 20/27 mg/m2 , long patient : 1 . Had least partial response prior carfilzomib therapy 2 . Was remove carfilzomib therapy due toxicity , unless approve medical monitor 3 . Was remove carfilzomib therapy progressive disease experience progressive disease within 6 month prior carfizolmib therapy Calculated measure creatinine clearance ( CrCl ) rate ≥ 30 mL/min calculate use formula Cockcroft Gault [ ( 140 − age ) × mass ( kg ) / ( 72 × serum creatinine mg/dL ) ] . Multiply result 0.85 female . Key Radiation therapy within 2 week prior first dose . Localized radiation therapy within 1 week prior first dose . Immunotherapy/standard myeloma therapy within 2 week ; prior stem cell transplant ( SCT ) therapy ( autologous SCT within prior 8 week ; allogeneic SCT within prior 16 week ) Participation investigational therapeutic study within 3 week prior first dose Prior oprozomib exposure Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose Other malignancy within past 3 year exception adequately treat basal cell carcinoma skin , squamous cell skin cancer , thyroid cancer , carcinoma situ cervix , carcinoma situ breast , prostate cancer Gleason Score 6 less stable prostate specific antigen level , cancer consider cure surgical resection . Plasma cell leukemia History previous clinically significant GI bleed last 6 month prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>oprozomib</keyword>
	<keyword>OPZ</keyword>
	<keyword>ONX 0912</keyword>
	<keyword>Onyx</keyword>
	<keyword>proteasome inhibitor</keyword>
	<keyword>oprozomib tablet</keyword>
</DOC>